194 related articles for article (PubMed ID: 29574444)
1. Opioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol.
Peacock A; Larance B; Farrell M; Cairns R; Buckley N; Degenhardt L
BMJ Open; 2018 Mar; 8(3):e020006. PubMed ID: 29574444
[TBL] [Abstract][Full Text] [Related]
2. Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study.
Peacock A; Gisev N; Memedovic S; Larance B; Brown J; Cairns R; Buckley N; Farrell M; Degenhardt L
Drug Alcohol Depend; 2020 Jan; 206():107697. PubMed ID: 31869601
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
[TBL] [Abstract][Full Text] [Related]
4. Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Australia: a protocol for a retrospective observational study.
Nielsen S; Crossin R; Middleton M; Martin C; Wilson J; Lam T; Scott D; Smith K; Lubman D
BMJ Open; 2019 May; 9(5):e029170. PubMed ID: 31138584
[TBL] [Abstract][Full Text] [Related]
5. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study.
Larance B; Dobbins T; Peacock A; Ali R; Bruno R; Lintzeris N; Farrell M; Degenhardt L
Lancet Psychiatry; 2018 Feb; 5(2):155-166. PubMed ID: 29336948
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System.
Vosburg SK; Severtson SG; Dart RC; Cicero TJ; Kurtz SP; Parrino MW; Green JL
J Pain; 2018 Apr; 19(4):439-453. PubMed ID: 29224919
[TBL] [Abstract][Full Text] [Related]
7. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment.
Butler SF; McNaughton EC; Black RA
Pain Med; 2015 Jan; 16(1):119-30. PubMed ID: 25243972
[TBL] [Abstract][Full Text] [Related]
8. Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids.
Peacock A; Bruno R; Cama E; Kihas I; Larance B; Lintzeris N; Hordern A; White N; Ali R; Degenhardt L
Drug Alcohol Rev; 2015 Nov; 34(6):611-22. PubMed ID: 26084592
[TBL] [Abstract][Full Text] [Related]
9. A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone.
Peacock A; Degenhardt L; Larance B; Cama E; Lintzeris N; Ali R; Bruno R
Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1321-33. PubMed ID: 26419615
[TBL] [Abstract][Full Text] [Related]
10. Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol.
Gisev N; Pearson SA; Dobbins T; Currow DC; Blyth F; Larney S; Dunlop A; Mattick RP; Wilson A; Degenhardt L
BMJ Open; 2018 Dec; 8(12):e025840. PubMed ID: 30518593
[TBL] [Abstract][Full Text] [Related]
11. The POPPY Research Programme protocol: investigating opioid utilisation, costs and patterns of extramedical use in Australia.
Degenhardt L; Blanch B; Gisev N; Larance B; Pearson S
BMJ Open; 2015 Jan; 5(1):e007030. PubMed ID: 25631315
[TBL] [Abstract][Full Text] [Related]
12. Harms associated with extramedical use of prescription opioid analgesics in Australia: A scoping review.
Lalic S; Jokanovic N; Ilomäki J; Gisev N; Lloyd B; Lubman DI; Bell JS
Res Social Adm Pharm; 2019 Aug; 15(8):925-935. PubMed ID: 30076092
[TBL] [Abstract][Full Text] [Related]
13. Diversion and Illicit Sale of Extended Release Tapentadol in the United States.
Dart RC; Surratt HL; Le Lait MC; Stivers Y; Bebarta VS; Freifeld CC; Brownstein JS; Burke JJ; Kurtz SP; Dasgupta N
Pain Med; 2016 Aug; 17(8):1490-6. PubMed ID: 26814267
[TBL] [Abstract][Full Text] [Related]
14. 'Extreme personal stress' and 'a lot of pain': Exploring the physical, mental and social contexts of extramedical pharmaceutical opioid use in Australian paramedic case descriptions.
Wilson J; Lam T; Scott D; Crossin R; Matthews S; Smith K; Lubman DI; Nielsen S
Drug Alcohol Rev; 2020 Nov; 39(7):870-878. PubMed ID: 32633445
[TBL] [Abstract][Full Text] [Related]
15. Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Victoria, Australia from 2013 to 2018.
Nielsen S; Crossin R; Middleton M; Lam T; Wilson J; Scott D; Martin C; Smith K; Lubman D
Addiction; 2020 Jun; 115(6):1075-1087. PubMed ID: 31742765
[TBL] [Abstract][Full Text] [Related]
16. Comparing opioid types in the persistence of opioid use following surgical admission: a study protocol for a retrospective observational linkage study comparing tapentadol and oxycodone in Australia.
Lam T; Biggs N; Xia T; Evans J; Stevens J; da Gama M; Lubman DI; Nielsen S
BMJ Open; 2022 Apr; 12(4):e060151. PubMed ID: 35418442
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the abuse of tapentadol immediate release: the first 24 months.
Dart RC; Cicero TJ; Surratt HL; Rosenblum A; Bartelson BB; Adams EH
J Opioid Manag; 2012; 8(6):395-402. PubMed ID: 23264317
[TBL] [Abstract][Full Text] [Related]
18. Quality use of publicly subsidised tapentadol in Australia: a population-based analysis.
Camacho X; Schaffer AL; Brett J; Pratt N; Buckley NA; Henry D; Pearson SA
Intern Med J; 2024 Jun; 54(6):941-950. PubMed ID: 38299430
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index-Multimedia Version (ASI-MV).
Vosburg SK; Beaumont J; Dailey-Govoni ST; Butler SF; Green JL
Pain Med; 2020 Sep; 21(9):1891-1901. PubMed ID: 31617931
[TBL] [Abstract][Full Text] [Related]
20. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
Coplan PM; Chilcoat HD; Butler SF; Sellers EM; Kadakia A; Harikrishnan V; Haddox JD; Dart RC
Clin Pharmacol Ther; 2016 Sep; 100(3):275-86. PubMed ID: 27170195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
